메뉴 건너뛰기




Volumn 58, Issue 4, 2013, Pages 1149-1156

The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease

Author keywords

Anti TNF; Crohn's disease; Hepatitis C virus infection; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; INFLIXIMAB; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

EID: 84876689569     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2457-0     Document Type: Article
Times cited : (22)

References (41)
  • 1
    • 44649187924 scopus 로고    scopus 로고
    • Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
    • 18550004 10.1016/j.cgh.2008.03.014 1:CAS:528:DC%2BD1cXos1WjsLg%3D
    • Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653.
    • (2008) Clin Gastroenterol Hepatol , vol.6 , pp. 644-653
    • Peyrin-Biroulet, L.1    Deltenre, P.2    De Suray, N.3
  • 2
    • 28844473957 scopus 로고    scopus 로고
    • Infliximab for induction and maintenance therapy for ulcerative colitis
    • 16339095 10.1056/NEJMoa050516 1:CAS:528:DC%2BD2MXhtlShurjE
    • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
    • (2005) N Engl J Med , vol.353 , pp. 2462-2476
    • Rutgeerts, P.1    Sandborn, W.J.2    Feagan, B.G.3
  • 3
    • 4644265354 scopus 로고    scopus 로고
    • Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease
    • 15472531 10.1097/00054725-200409000-00025
    • Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:657-660.
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 657-660
    • Velayos, F.S.1    Sandborn, W.J.2
  • 4
    • 41349088375 scopus 로고    scopus 로고
    • Risk factors for opportunistic infections in patients with inflammatory bowel disease
    • 18294633 10.1053/j.gastro.2008.01.012
    • Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
    • (2008) Gastroenterology , vol.134 , pp. 929-936
    • Toruner, M.1    Loftus Jr., E.V.2    Harmsen, W.S.3
  • 5
    • 1842479859 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C
    • 15057920 10.1002/hep.20119
    • Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
    • (2004) Hepatology , vol.39 , pp. 1147-1171
    • Strader, D.B.1    Wright, T.2    Thomas, D.L.3
  • 6
    • 0031887203 scopus 로고    scopus 로고
    • Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection
    • 9486392 10.1046/j.1365-2249.1998.00469.x 1:STN:280:DyaK1c7ksFOqtQ%3D%3D
    • Kallinowski B, Haseroth K, Marinos G, et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 1998;111:269-277.
    • (1998) Clin Exp Immunol , vol.111 , pp. 269-277
    • Kallinowski, B.1    Haseroth, K.2    Marinos, G.3
  • 7
    • 0029871106 scopus 로고    scopus 로고
    • IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C
    • 8601375 10.1007/BF02093821 1:CAS:528:DyaK28XitV2hu7Y%3D
    • Kishihara Y, Hayashi J, Yoshimura E, et al. IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci. 1996;41:315-321.
    • (1996) Dig Dis Sci , vol.41 , pp. 315-321
    • Kishihara, Y.1    Hayashi, J.2    Yoshimura, E.3
  • 8
    • 0031427384 scopus 로고    scopus 로고
    • Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection
    • 9440625 10.1023/A:1018804426724 1:STN:280:DyaK1c7gtFGktw%3D%3D
    • Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42:2487-2494.
    • (1997) Dig Dis Sci , vol.42 , pp. 2487-2494
    • Nelson, D.R.1    Lim, H.L.2    Marousis, C.G.3
  • 9
    • 12644302184 scopus 로고    scopus 로고
    • Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C
    • 9021719 1:STN:280:DyaK2s7ntlyhsg%3D%3D
    • Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver. 1996;16:390-399.
    • (1996) Liver , vol.16 , pp. 390-399
    • Fukuda, R.1    Ishimura, N.2    Ishihara, S.3
  • 10
    • 0030052322 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C
    • 8591843 1:STN:280:DyaK287mt1SnsA%3D%3D
    • Larrea E, Garcia N, Qian C, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology. 1996;23:210-217.
    • (1996) Hepatology , vol.23 , pp. 210-217
    • Larrea, E.1    Garcia, N.2    Qian, C.3
  • 11
    • 7044270670 scopus 로고    scopus 로고
    • Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: Hepatitis C, hepatitis B, and HIV infection
    • 15479865 10.1136/ard.2004.028209 1:CAS:528:DC%2BD2cXhtVajtr3M
    • Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63:ii18-ii24.
    • (2004) Ann Rheum Dis , vol.63
    • Calabrese, L.H.1    Zein, N.2    Vassilopoulos, D.3
  • 12
    • 13844294333 scopus 로고    scopus 로고
    • Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study
    • 15791697 10.1016/j.jhep.2004.11.025 1:CAS:528:DC%2BD2MXhtlensr0%3D
    • Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315-322.
    • (2005) J Hepatol , vol.42 , pp. 315-322
    • Zein, N.N.1
  • 13
    • 0019319257 scopus 로고
    • A simple index of Crohn's-disease activity
    • 6102236 10.1016/S0140-6736(80)92767-1 1:STN:280:DyaL3c7kt1Wjtg%3D%3D
    • Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
    • (1980) Lancet , vol.1 , pp. 514
    • Harvey, R.F.1    Bradshaw, J.M.2
  • 14
    • 0023521441 scopus 로고
    • Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
    • 3317057 10.1056/NEJM198712243172603 1:STN:280:DyaL1c%2FmsFOkuw%3D%3D
    • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
    • (1987) N Engl J Med , vol.317 , pp. 1625-1629
    • Schroeder, K.W.1    Tremaine, W.J.2    Ilstrup, D.M.3
  • 15
    • 59849104111 scopus 로고    scopus 로고
    • Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
    • 18623174 10.1002/ibd.20520
    • Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
    • (2008) Inflamm Bowel Dis , vol.14 , pp. 1660-1666
    • Lewis, J.D.1    Chuai, S.2    Nessel, L.3
  • 16
    • 77949652854 scopus 로고    scopus 로고
    • Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity
    • 20096379 10.1016/j.cgh.2010.01.001
    • Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363.
    • (2010) Clin Gastroenterol Hepatol , vol.8 , pp. 357-363
    • Vermeire, S.1    Schreiber, S.2    Sandborn, W.J.3
  • 17
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C: An update
    • 19330875 10.1002/hep.22759 1:CAS:528:DC%2BD1MXkslWjs7o%3D
    • Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3
  • 18
    • 34249065208 scopus 로고    scopus 로고
    • Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease
    • 17531027 10.1111/j.1572-0241.2007.01131.x
    • Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol. 2007;102:1333-1334.
    • (2007) Am J Gastroenterol , vol.102 , pp. 1333-1334
    • Abdelmalek, M.F.1    Liu, C.2    Valentine, J.F.3
  • 19
    • 0035135319 scopus 로고    scopus 로고
    • Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection
    • 11246620 10.1097/00042737-200102000-00016 1:STN:280: DC%2BD3M3ksVOrtA%3D%3D
    • Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001;13:191-192.
    • (2001) Eur J Gastroenterol Hepatol , vol.13 , pp. 191-192
    • Campbell, S.1    Ghosh, S.2
  • 20
    • 0037280276 scopus 로고    scopus 로고
    • Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF
    • 12591081 10.1111/j.1572-0241.2003.07245.x
    • Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol. 2003;98:504-505.
    • (2003) Am J Gastroenterol , vol.98 , pp. 504-505
    • Holtmann, M.H.1    Galle, P.R.2    Neurath, M.F.3
  • 21
    • 0036165844 scopus 로고    scopus 로고
    • Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection
    • 11845808 10.1053/gast.2002.31602
    • Biancone L, Del Vecchio Blanco G, Pallone F, et al. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology. 2002;122:593-594.
    • (2002) Gastroenterology , vol.122 , pp. 593-594
    • Biancone, L.1    Del Vecchio Blanco, G.2    Pallone, F.3
  • 22
    • 77957325399 scopus 로고    scopus 로고
    • Inflammatory bowel disease and hepatitis B and C in Western Balkans: A referral centre study and review of the literature
    • 21122543 10.1016/j.crohns.2010.03.001
    • Katsanos KH, Tsianos VE, Zois CD, et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis. 2010;4:450-465.
    • (2010) J Crohns Colitis , vol.4 , pp. 450-465
    • Katsanos, K.H.1    Tsianos, V.E.2    Zois, C.D.3
  • 23
    • 71449100743 scopus 로고    scopus 로고
    • Inflammatory bowel disease and hepatitis B and C
    • 19896313 10.1016/j.gcb.2009.03.021
    • Chevaux JB, Bigard MA, Bensenane M, et al. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009;33:1082-1093.
    • (2009) Gastroenterol Clin Biol , vol.33 , pp. 1082-1093
    • Chevaux, J.B.1    Bigard, M.A.2    Bensenane, M.3
  • 24
    • 72049091520 scopus 로고    scopus 로고
    • The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease
    • 19855102 10.1093/bmb/ldp036 1:CAS:528:DC%2BD1MXhsFOht7rN
    • Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull. 2009;92:61-77.
    • (2009) Br Med Bull , vol.92 , pp. 61-77
    • Shale, M.J.1
  • 25
    • 71449093991 scopus 로고    scopus 로고
    • Review article: Chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease
    • 19681818 10.1111/j.1365-2036.2009.04112.x 1:CAS:528: DC%2BC3cXnvFClsQ%3D%3D
    • Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20-34.
    • (2010) Aliment Pharmacol Ther , vol.31 , pp. 20-34
    • Shale, M.J.1    Seow, C.H.2    Coffin, C.S.3
  • 26
    • 67349251600 scopus 로고    scopus 로고
    • Hepatitis C virus and inflammatory bowel disease
    • 18975088 10.1007/s10620-008-0489-2
    • Horn TL, Reynolds J, de Villiers W, et al. Hepatitis C virus and inflammatory bowel disease. Dig Dis Sci. 2009;54:1171-1177.
    • (2009) Dig Dis Sci , vol.54 , pp. 1171-1177
    • Horn, T.L.1    Reynolds, J.2    De Villiers, W.3
  • 27
    • 0035158696 scopus 로고    scopus 로고
    • Hepatitis B and C virus infection in Crohn's disease
    • 11720317 10.1097/00054725-200111000-00002 1:STN:280: DC%2BD3MnnsVeltw%3D%3D
    • Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001;7:287-294.
    • (2001) Inflamm Bowel Dis , vol.7 , pp. 287-294
    • Biancone, L.1    Pavia, M.2    Del Vecchio Blanco, G.3
  • 28
    • 77957188851 scopus 로고    scopus 로고
    • Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy
    • 20577000 10.1136/gut.2010.208413 1:STN:280:DC%2BC3cfivVOnug%3D%3D
    • Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340-1346.
    • (2010) Gut , vol.59 , pp. 1340-1346
    • Loras, C.1    Gisbert, J.P.2    Minguez, M.3
  • 29
    • 60749113827 scopus 로고    scopus 로고
    • Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide, multicenter study
    • 19098850 10.1038/ajg.2008.4 1:CAS:528:DC%2BD1MXht1Sgsg%3D%3D
    • Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol. 2009;104:57-63.
    • (2009) Am J Gastroenterol , vol.104 , pp. 57-63
    • Loras, C.1    Saro, C.2    Gonzalez-Huix, F.3
  • 30
    • 77952679364 scopus 로고    scopus 로고
    • Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France
    • 19885908 10.1002/ibd.21147
    • Chevaux JB, Nani A, Oussalah A, et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010;16:916-924.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 916-924
    • Chevaux, J.B.1    Nani, A.2    Oussalah, A.3
  • 31
    • 33745929069 scopus 로고    scopus 로고
    • Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: A case study and review of the literature
    • 16369233
    • Alderson JW, Van Dinter TG Jr, Opatowsky MJ, et al. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. MedGenMed. 2005;7:7.
    • (2005) MedGenMed , vol.7 , pp. 7
    • Alderson, J.W.1    Van Dinter Jr., T.G.2    Opatowsky, M.J.3
  • 32
    • 54949145730 scopus 로고    scopus 로고
    • Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection
    • 18688917 1:CAS:528:DC%2BD1cXhtlWit7nI
    • Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35:1944-1949.
    • (2008) J Rheumatol , vol.35 , pp. 1944-1949
    • Ferri, C.1    Ferraccioli, G.2    Ferrari, D.3
  • 33
    • 33845585614 scopus 로고    scopus 로고
    • Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus
    • 10.1093/rheumatology/kel191 1:CAS:528:DC%2BD28XhtlChtbbL
    • Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford). 2007;46:97-99.
    • (2007) Rheumatology (Oxford) , vol.46 , pp. 97-99
    • Marotte, H.1    Fontanges, E.2    Bailly, F.3
  • 34
    • 0142218784 scopus 로고    scopus 로고
    • Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection
    • 14583571 10.1136/ard.62.11.1078 1:CAS:528:DC%2BD3sXpsVSks7c%3D
    • Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078-1082.
    • (2003) Ann Rheum Dis , vol.62 , pp. 1078-1082
    • Peterson, J.R.1    Hsu, F.C.2    Simkin, P.A.3
  • 35
    • 0033631713 scopus 로고    scopus 로고
    • Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors
    • 10679588 1:STN:280:DC%2BD3c7ksFyiuw%3D%3D
    • Longo F, Hebuterne X, Tran A, et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol. 2000;24:77-81.
    • (2000) Gastroenterol Clin Biol , vol.24 , pp. 77-81
    • Longo, F.1    Hebuterne, X.2    Tran, A.3
  • 36
    • 0030589563 scopus 로고    scopus 로고
    • Suppression of apoptotic cell death by hepatitis C virus core protein
    • 8955036 10.1006/viro.1996.0644 1:CAS:528:DyaK28XnsF2ktbc%3D
    • Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology. 1996;226:176-182.
    • (1996) Virology , vol.226 , pp. 176-182
    • Ray, R.B.1    Meyer, K.2    Ray, R.3
  • 37
    • 0031892177 scopus 로고    scopus 로고
    • Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein
    • 9442069 10.1074/jbc.273.4.2256 1:CAS:528:DyaK1cXnsVKrtg%3D%3D
    • Ray RB, Meyer K, Steele R, et al. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem. 1998;273:2256-2259.
    • (1998) J Biol Chem , vol.273 , pp. 2256-2259
    • Ray, R.B.1    Meyer, K.2    Steele, R.3
  • 38
    • 33749627330 scopus 로고    scopus 로고
    • How to modulate inflammatory cytokines in liver diseases
    • 17032402 10.1111/j.1478-3231.2006.01339.x 1:CAS:528:DC%2BD28Xht12mtbnN
    • Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int. 2006;26:1029-1039.
    • (2006) Liver Int , vol.26 , pp. 1029-1039
    • Tilg, H.1    Kaser, A.2    Moschen, A.R.3
  • 39
    • 0026691627 scopus 로고
    • Serum levels of cytokines in chronic liver diseases
    • 1612333 1:CAS:528:DyaK38XkvVOrt7s%3D
    • Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103:264-274.
    • (1992) Gastroenterology , vol.103 , pp. 264-274
    • Tilg, H.1    Wilmer, A.2    Vogel, W.3
  • 40
    • 0028153997 scopus 로고
    • Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis
    • 7509363 10.1084/jem.179.3.841 1:CAS:528:DyaK2cXhs1Wgtr4%3D
    • Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med. 1994;179:841-848.
    • (1994) J Exp Med , vol.179 , pp. 841-848
    • Gonzalez-Amaro, R.1    Garcia-Monzon, C.2    Garcia-Buey, L.3
  • 41
    • 0034754477 scopus 로고    scopus 로고
    • Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
    • 11677200 10.1053/gast.2001.28674 1:CAS:528:DC%2BD3MXpt1SrsLk%3D
    • Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
    • (2001) Gastroenterology , vol.121 , pp. 1088-1094
    • Sandborn, W.J.1    Hanauer, S.B.2    Katz, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.